Related Experiment Video
Updated: Jul 27, 2026
08:30
Encapsulation Thermogenic Preadipocytes for Transplantation into Adipose Tissue Depots
Published on: June 2, 2015
Alpha-lipoic acid, an anti-obesity agent?
1School of Biomedical Sciences, The University of Queensland, Australia. s_doggrell@yahoo.com
Expert Opinion on Investigational Drugs
|November 30, 2004
Summary
Alpha-lipoic acid supplementation in rats reduced body weight and food intake while increasing energy expenditure. Further research is needed to confirm these anti-obesity effects for human clinical trials.
Area of Science:
- Metabolic research
- Nutritional science
- Obesity research
Background:
- Obesity is a significant health concern, reducing life expectancy and increasing risks for hypertension and Type 2 diabetes.
- Identifying effective interventions for obesity management is crucial.
Purpose of the Study:
- To investigate the anti-obesity effects of alpha-lipoic acid in animal models.
- To explore the underlying mechanisms of alpha-lipoic acid's action on metabolism.
Main Methods:
- Administration of alpha-lipoic acid (0.5% weight/weight) to Sprague-Dawley and Otsuka Long-Evans Tokushima Fatty rats.
- Monitoring of body weight, food intake, and whole-body energy expenditure.
- Analysis of hypothalamic AMP-activated protein kinase activity.
Main Results:
- Alpha-lipoic acid supplementation significantly reduced body weight and food intake in rats.
- Whole-body energy expenditure was increased following alpha-lipoic acid administration.
- The anti-obesity effects were associated with the suppression of hypothalamic AMP-activated protein kinase.
Conclusions:
- Alpha-lipoic acid demonstrates potential as an anti-obesity agent in preclinical models.
- Suppression of hypothalamic AMP-activated protein kinase is a key mechanism.
- Long-term studies are necessary to validate these findings for human obesity treatment.
Related Concept Videos
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...